Janus Henderson Group PLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 1,188,191 shares of the company’s stock, valued at approximately $30,329,000.

Several other institutional investors have also modified their holdings of BCAX. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $229,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Bicara Therapeutics during the third quarter valued at $462,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at $582,000. Walleye Capital LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $809,000. Finally, Vestal Point Capital LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $10,825,000.

Analysts Set New Price Targets

A number of research firms recently weighed in on BCAX. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective on the stock. Stifel Nicolaus began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price target on the stock. HC Wainwright assumed coverage on Bicara Therapeutics in a report on Friday. They set a “buy” rating and a $42.00 price objective for the company. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Trading Up 8.0 %

Shares of NASDAQ:BCAX opened at $21.10 on Friday. The business has a 50 day moving average price of $21.73. Bicara Therapeutics Inc. has a 52-week low of $17.41 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts predict that Bicara Therapeutics Inc. will post -2.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 8.46 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares of the company’s stock, valued at $77,461,524. This represents a 74.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.